Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Signalling by the epidermal growth factor receptor (EGFR) controls morphogenesis and/or homeostasis of several tissues from worms to mammals. The correct execution of these programmes requires the generation of EGFR signals of appropriate strength and duration. This is obtained through a complex circuitry of positive and negative feedback regulation. Feedback inhibitory mechanisms restrain EGFR activity in time and space, which is key to ensuring that receptor outputs are commensurate to the cell and tissue needs. Here, we focus on the emerging field of inducible negative feedback regulation of the EGFR in mammals. In mammalian cells, four EGFR inducible feedback inhibitors (IFIs), namely LRIG1, RALT (also known as MIG6 and ERRFI1), SOCS4 and SOCS5, have been discovered recently. EGFR IFIs are expressed de novo in the context of early or delayed transcriptional responses triggered by EGFR activation. They all bind to the EGFR and suppress receptor signalling through several mechanisms, including catalytic inhibition and receptor downregulation. Here, we review the mechanistic basis of IFI signalling and rationalise the function of IFIs in light of gene-knockout studies that assign LRIG1 and RALT an essential role in restricting cell proliferation. Finally, we discuss how IFIs might participate in system control of EGFR signalling and highlight the emerging roles for IFIs in the suppression of EGFR-driven tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“Notable features of all these ligands are their inability to drive substantial EGFR downregulation (Roepstorff et al., 2009) and their ability to elicit broad ErbB activation (Yarden and Sliwkowski, 2001).”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · cited 1×
“Inducible feedback inhibitors as tumour suppressors EGFR and ERBB2 are established cancer-causing genes (Futreal et al., 2004; Santarius et al., 2010), and recent work also points to ERBB3 (Mills and Yarden, 2010) and ERBB4 (Prickett et al., 2009) signalling as being relevant to cancer pathogenesis.”
BackgroundMalignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316 · cited 5×
“In GBMs without 1p36 deletions, promoter methylation, as shown in samples of papillary thyroid carcinoma (Lin et al., 2011), might account for loss of RALT expression, although this has not been addressed experimentally.”
BackgroundInfluentialAn allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 2×
“This process is thought to be reversible, with the receiver subsequently acting as the activator (Zhang et al., 2006).”
BackgroundInhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
Zhang, X., Pickin, K. A., Bose, R., Jura, N., Cole, P. A., & Kuriyan, J. (2007) · Nature · doi:10.1038/nature05998 · Cited by 357
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352 · cited 1×
“Inducible feedback inhibitors as tumour suppressors EGFR and ERBB2 are established cancer-causing genes (Futreal et al., 2004; Santarius et al., 2010), and recent work also points to ERBB3 (Mills and Yarden, 2010) and ERBB4 (Prickett et al., 2009) signalling as being relevant to cancer pathogenesis.”
BackgroundCross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells*
Jo, M., Stolz, D. B., Esplen, J. E., Dorko, K., Michalopoulos, G. K., & Strom, S. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8806 · Cited by 347
The EGF receptor is required for efficient liver regeneration
Natarajan, A., Wagner, B., & Sibilia, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704126104 · Cited by 320
Negative Regulation of the EGFR-MAPK Cascade by Actin-MAL-Mediated Mig6/Errfi-1 Induction
Descot, A., Hoffmann, R., Shaposhnikov, D., Reschke, M., Ullrich, A., & Posern, G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.015 · Cited by 128 · cited 1×
“RALT expression is upregulated by stimuli as diverse as growth factors, hypoxia, mechanical and osmotic stress, steroid hormones, retinoic acid (Zhang and Vande Woude, 2007) and actin dynamics (Descot et al., 2009).”
BackgroundFrosi, Y., Anastasi, S., Ballarò, C., Varsano, G., Castellani, L., Maspero, E., Polo, S., Alemà, S., & Segatto, O. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201002032 · Cited by 125
Self-citationGrowth factor‐dependent signaling and cell cycle progression
Jones, S. M., & Kazlauskas, A. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02113-5 · Cited by 124 · cited 1×
“Inducible feedback inhibitors as gatekeepers of EGFR mitogenic signalling Progression through G1 and entry into S phase of the cell cycle requires sustained mitogenic signals (Jones and Kazlauskas, 2001).”
BackgroundJeong, J.-W., Lee, H. S., Lee, K. Y., White, L. D., Broaddus, R. R., Zhang, Y.-W., Vande Woude, G. F., Giudice, L. C., Young, S. L., Lessey, B. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903632106 · Cited by 92
Cited by
Mukherji, A., Kobiita, A., Ye, T., & Chambon, P. (2013) · Cell · doi:10.1016/j.cell.2013.04.020 · Cited by 560
Cutano, V., Di Giorgio, E., Minisini, M., Picco, R., Dalla, E., & Brancolini, C. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12503 · Cited by 44
Pathways driving the endocytosis of mutant and wild-type EGFR in cancer
Hampton, K. K., & Craven, R. J. (2014) · Oncoscience · doi:10.18632/oncoscience.67 · Cited by 35
Yu, S., Yang, M., Lim, K.-M., Cho, Y., Kim, H., Lee, K., Jeong, S.-H., Coffey, R. J., Goldenring, J. R., & Nam, K. T. (2018) · The American Journal of Pathology · doi:10.1016/j.ajpath.2018.08.006 · Cited by 19
Metadata
- Authors
- Segatto, O., Anastasi, S., & Alemà, S.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2011-06-01
- Volume
- 124
- Issue
- 11
- Pages
- 1785-1793
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W2153322850
- Cited by
- 103
- References
- 13
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.